<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00713765</url>
  </required_header>
  <id_info>
    <org_study_id>D3690C00005</org_study_id>
    <secondary_id>EudraCt No.2008-002847-17</secondary_id>
    <nct_id>NCT00713765</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction Between AZD3480 and Donepezil</brief_title>
  <official_title>A Double-blind, Randomised, Cross-over, Placebo-controlled Study of Repeated Oral Doses of AZD3480 and a Single Dose of Donepezil to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Donepezil in Healthy Extensive and Poor Metabolisers of CYP2D6</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to 1) examine the effects of AZD3480 and donepezil on the blood
      concentrations of each other and 2) assess the safety and tolerability of the combined
      administration of AZD3480 with donepezil.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Ended prematurely - The trial never commenced.
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK variables</measure>
    <time_frame>Frequent sampling occasions during</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables (adverse events, blood pressure, pulse, safety lab)</measure>
    <time_frame>During the whole treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3480 + Donepezil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3480</intervention_name>
    <description>18 total doses of 40 mg, on days 1-18</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>One single dose of mg on day 5</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study-specific procedures

          -  BMI between 18 and 30 kg/m2

          -  Medical and surgical history and physical examination without any clinically
             significant findings

          -  Genotyped as an EM, defined in this study as having ≥ 1.5 functional CYP2D6 alleles,
             or a PM, defined as having zero functional CYP2D6 alleles

        Exclusion Criteria:

          -  History of clinically significant cardio- or cerebrovascular, pulmonary, renal,
             hepatic, neurological, mental or gastrointestinal disorder or any other major disorder
             that may interfere with the objectives of the study, as judged by the Investigator

          -  Clinically significant illness as judged by the Investigator, within two weeks before
             the first administration of investigational product

          -  Female subjects who have a positive pregnancy test or who are pregnant or
             breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Göran Hårdemark</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Sodertalje, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon Constable</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON Development Solutions, Manchester, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1367&amp;filename=D3690C00005.pdf</url>
    <description>D3690C00005_No_Results_Certificate</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2008</study_first_submitted>
  <study_first_submitted_qc>July 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2008</study_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

